CN116808172B - 葵花盘肽、复合脂质体及其在制备降低尿酸和溶解痛风石产品中的应用 - Google Patents
葵花盘肽、复合脂质体及其在制备降低尿酸和溶解痛风石产品中的应用 Download PDFInfo
- Publication number
- CN116808172B CN116808172B CN202310022311.7A CN202310022311A CN116808172B CN 116808172 B CN116808172 B CN 116808172B CN 202310022311 A CN202310022311 A CN 202310022311A CN 116808172 B CN116808172 B CN 116808172B
- Authority
- CN
- China
- Prior art keywords
- sunflower disc
- sunflower
- peptide
- ferrocene
- liposome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000208818 Helianthus Species 0.000 title claims abstract description 142
- 235000003222 Helianthus annuus Nutrition 0.000 title claims abstract description 142
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 78
- 239000002502 liposome Substances 0.000 title claims abstract description 67
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims abstract description 44
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title claims abstract description 43
- 229940116269 uric acid Drugs 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title claims description 17
- 239000002131 composite material Substances 0.000 title description 3
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 claims abstract description 38
- 229930013930 alkaloid Natural products 0.000 claims abstract description 31
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 43
- 239000000243 solution Substances 0.000 claims description 39
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 31
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 30
- 229930003935 flavonoid Natural products 0.000 claims description 22
- 150000002215 flavonoids Chemical class 0.000 claims description 22
- 235000017173 flavonoids Nutrition 0.000 claims description 22
- 238000006243 chemical reaction Methods 0.000 claims description 19
- 239000007787 solid Substances 0.000 claims description 19
- 150000003904 phospholipids Chemical class 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 238000001035 drying Methods 0.000 claims description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 15
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 14
- 239000003480 eluent Substances 0.000 claims description 14
- 239000012071 phase Substances 0.000 claims description 14
- 239000008055 phosphate buffer solution Substances 0.000 claims description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 12
- 238000005406 washing Methods 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 10
- 239000000047 product Substances 0.000 claims description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 9
- 239000008346 aqueous phase Substances 0.000 claims description 9
- 238000001704 evaporation Methods 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 9
- 239000000469 ethanolic extract Substances 0.000 claims description 8
- 230000002829 reductive effect Effects 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 claims description 7
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 6
- -1 amino ferrocene Chemical compound 0.000 claims description 6
- 125000003277 amino group Chemical group 0.000 claims description 6
- 235000012000 cholesterol Nutrition 0.000 claims description 6
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 229940083466 soybean lecithin Drugs 0.000 claims description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
- 238000005903 acid hydrolysis reaction Methods 0.000 claims description 5
- MYCZBBOLTYBTCX-UHFFFAOYSA-N cyclopenta-2,4-dien-1-amine;cyclopenta-1,3-diene;iron(2+) Chemical compound [Fe+2].C=1C=C[CH-]C=1.NC1=CC=C[CH-]1 MYCZBBOLTYBTCX-UHFFFAOYSA-N 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 239000012047 saturated solution Substances 0.000 claims description 5
- 238000009210 therapy by ultrasound Methods 0.000 claims description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 3
- 239000013078 crystal Substances 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 239000011521 glass Substances 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 239000011347 resin Substances 0.000 claims description 3
- 229920005989 resin Polymers 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 201000001431 Hyperuricemia Diseases 0.000 abstract description 17
- 239000002994 raw material Substances 0.000 abstract description 15
- 150000003797 alkaloid derivatives Chemical class 0.000 abstract description 14
- 229930003944 flavone Natural products 0.000 abstract description 13
- 235000011949 flavones Nutrition 0.000 abstract description 13
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 abstract description 12
- 150000002212 flavone derivatives Chemical class 0.000 abstract description 12
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 abstract description 12
- 206010061218 Inflammation Diseases 0.000 abstract description 10
- 230000004054 inflammatory process Effects 0.000 abstract description 10
- 230000000968 intestinal effect Effects 0.000 abstract description 5
- 230000036772 blood pressure Effects 0.000 abstract description 4
- 238000001727 in vivo Methods 0.000 abstract description 4
- 208000002193 Pain Diseases 0.000 abstract description 3
- 102100033220 Xanthine oxidase Human genes 0.000 abstract description 3
- 108010093894 Xanthine oxidase Proteins 0.000 abstract description 3
- 210000005229 liver cell Anatomy 0.000 abstract description 3
- 201000005569 Gout Diseases 0.000 abstract description 2
- 230000029142 excretion Effects 0.000 abstract description 2
- 230000036039 immunity Effects 0.000 abstract description 2
- 210000003292 kidney cell Anatomy 0.000 abstract description 2
- 230000008855 peristalsis Effects 0.000 abstract description 2
- 230000008439 repair process Effects 0.000 abstract description 2
- 239000004575 stone Substances 0.000 abstract description 2
- 230000008961 swelling Effects 0.000 abstract description 2
- 230000002194 synthesizing effect Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 53
- 230000000694 effects Effects 0.000 description 29
- 238000012360 testing method Methods 0.000 description 21
- 230000000052 comparative effect Effects 0.000 description 19
- 230000014509 gene expression Effects 0.000 description 18
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- 229940088598 enzyme Drugs 0.000 description 13
- 210000002919 epithelial cell Anatomy 0.000 description 12
- 241000700159 Rattus Species 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 108010078791 Carrier Proteins Proteins 0.000 description 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 210000004379 membrane Anatomy 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 108010090306 Member 2 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 description 7
- 102000013013 Member 2 Subfamily G ATP Binding Cassette Transporter Human genes 0.000 description 7
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 238000005538 encapsulation Methods 0.000 description 6
- 210000003494 hepatocyte Anatomy 0.000 description 6
- 238000004506 ultrasonic cleaning Methods 0.000 description 6
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 5
- 108091007960 PI3Ks Proteins 0.000 description 5
- 108091008611 Protein Kinase B Proteins 0.000 description 5
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 description 5
- 210000004347 intestinal mucosa Anatomy 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- LVNGJLRDBYCPGB-UHFFFAOYSA-N 1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-UHFFFAOYSA-N 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 210000001258 synovial membrane Anatomy 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 3
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 3
- 241000209140 Triticum Species 0.000 description 3
- 235000021307 Triticum Nutrition 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 229960005305 adenosine Drugs 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 229960005101 febuxostat Drugs 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000002329 infrared spectrum Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000005222 synovial tissue Anatomy 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 108010031154 Transcription Factor RelA Proteins 0.000 description 2
- SFCXYSXJRRDDNZ-UHFFFAOYSA-N [N].N1C(=O)NC(=O)C2=C1NC(=O)N2 Chemical compound [N].N1C(=O)NC(=O)C2=C1NC(=O)N2 SFCXYSXJRRDDNZ-UHFFFAOYSA-N 0.000 description 2
- 238000010306 acid treatment Methods 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229930004069 diterpene Natural products 0.000 description 2
- 125000000567 diterpene group Chemical group 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- QARYADFHOUHDSW-UHFFFAOYSA-M potassium 2H-oxazine-3-carboxylate Chemical compound O1NC(=CC=C1)C(=O)[O-].[K+] QARYADFHOUHDSW-UHFFFAOYSA-M 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000001338 self-assembly Methods 0.000 description 2
- 229930004725 sesquiterpene Natural products 0.000 description 2
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 2
- 229930009674 sesquiterpene lactone Natural products 0.000 description 2
- 150000002107 sesquiterpene lactone derivatives Chemical class 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 102000005747 Transcription Factor RelA Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229960002708 antigout preparations Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- DUEPRVBVGDRKAG-UHFFFAOYSA-N carbofuran Chemical compound CNC(=O)OC1=CC=CC2=C1OC(C)(C)C2 DUEPRVBVGDRKAG-UHFFFAOYSA-N 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229930003658 monoterpene Natural products 0.000 description 1
- 150000002773 monoterpene derivatives Chemical class 0.000 description 1
- 235000002577 monoterpenes Nutrition 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 108010067999 preproalbumin Proteins 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000020238 sunflower seed Nutrition 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
序列名称 | 核苷酸序列(5’→3’) |
TLR4-F | ctccattcaagcccaagcct,SEQ ID NO.12所示 |
TLR4-R | gtccttccatgacagaacggt,SEQ ID NO.13所示 |
AKT-F | caggaccacgagaagctgtt,SEQ ID NO.14所示 |
AKT-R | gatctccttggcatcctcgg,SEQ ID NO.15所示 |
PI3K-F | ggagaaccagccctaagctc,SEQ ID NO.16所示 |
PI3K-R | cagtgatggggttttgcagc,SEQ ID NO.17所示 |
NF-kBp65-F | atgcccaacttctccgacag,SEQ ID NO.18所示 |
NF-kBp65-R | aggacttccggtactccctc,SEQ ID NO.19所示 |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310022311.7A CN116808172B (zh) | 2023-01-07 | 2023-01-07 | 葵花盘肽、复合脂质体及其在制备降低尿酸和溶解痛风石产品中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310022311.7A CN116808172B (zh) | 2023-01-07 | 2023-01-07 | 葵花盘肽、复合脂质体及其在制备降低尿酸和溶解痛风石产品中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116808172A CN116808172A (zh) | 2023-09-29 |
CN116808172B true CN116808172B (zh) | 2024-02-13 |
Family
ID=88115537
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310022311.7A Active CN116808172B (zh) | 2023-01-07 | 2023-01-07 | 葵花盘肽、复合脂质体及其在制备降低尿酸和溶解痛风石产品中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116808172B (zh) |
Citations (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011079410A1 (zh) * | 2009-12-28 | 2011-07-07 | Ling Peixue | 含向日葵提取物的药物组合物、制备方法及用途 |
CN104523772A (zh) * | 2014-12-08 | 2015-04-22 | 浙江工业大学 | 黄蜀葵花生物总碱提取物及其制备方法与应用 |
WO2015181393A1 (en) * | 2014-05-30 | 2015-12-03 | Per-Johan Jakobsson | Novel sfti and cyclotide based peptides |
CN105125610A (zh) * | 2015-09-16 | 2015-12-09 | 吉林大学 | 葵花盘水解复合粉剂在制备治疗或缓解高尿酸痛风症药物中的应用 |
CN105753935A (zh) * | 2016-05-06 | 2016-07-13 | 洮南市金塔生物科技有限公司 | 一种葵花盘小分子肽及制备方法和医用用途 |
CN105878322A (zh) * | 2016-05-06 | 2016-08-24 | 洮南市金塔生物科技有限公司 | 一种结晶酶解法制备的葵花盘提取物及其制备方法 |
CN105920067A (zh) * | 2016-05-06 | 2016-09-07 | 洮南市金塔生物科技有限公司 | 一种含多糖、黄酮和生物碱的葵花盘提取物及其制备方法 |
CN107961366A (zh) * | 2018-01-15 | 2018-04-27 | 吉林省倍减生物科技有限公司 | 葵花小分子肽在降尿酸溶解痛风石修复肾功能中的应用 |
AU2018100458A4 (en) * | 2018-04-14 | 2018-06-21 | Jilin Province Beijian Biological Technology Co., Ltd. | Application Of Sunflower Small Molecule Peptide In The Repair Of Renal Function By Decreasing Uric Acid And Dissolving Chalk Stones |
CN108324938A (zh) * | 2018-03-01 | 2018-07-27 | 中国科学院过程工程研究所 | 一种颗粒型佐剂及其制备方法和应用 |
CN108354956A (zh) * | 2018-03-08 | 2018-08-03 | 吉林大学 | 葵花盘粉及其有效成分在制备修复受损肝细胞药物中的应用 |
CN108379318A (zh) * | 2018-05-31 | 2018-08-10 | 吉林大学 | 一种具有黄嘌呤氧化酶抑制活性的向日葵花盘水提物、制备方法及其应用 |
CN108434189A (zh) * | 2018-05-21 | 2018-08-24 | 长春市万象鹰豪商贸有限公司 | 一种向日葵花盘总黄酮及其提取工艺和应用 |
CN110251545A (zh) * | 2019-06-20 | 2019-09-20 | 中国药科大学 | 一种葵花盘提取物及其制备方法和应用 |
CN110354079A (zh) * | 2019-08-28 | 2019-10-22 | 中国药科大学 | 一种脂质过氧化物生成器及其制备方法和应用 |
RU2714891C1 (ru) * | 2019-10-15 | 2020-02-20 | Общество С Ограниченной Ответственностью "Научно-Исследовательская Фирма "Ультрасан" (Ооо Ниф "Ультрасан") | Ферроценилалкильные производные дипиразолилселенидов в качестве биологически активных соединений и способы их получения (варианты) |
AU2020101274A4 (en) * | 2020-05-14 | 2020-08-13 | Jilin Province TeyiFood Biotechnology Company Limited | Sunflower disc extract and medical use thereof in the treatment of constipation |
CN112505117A (zh) * | 2020-11-11 | 2021-03-16 | 军事科学院军事医学研究院军事兽医研究所 | 一种二茂铁纳米花、电化学适配体生物传感器体系及其制备方法和应用 |
CN112641760A (zh) * | 2021-01-08 | 2021-04-13 | 东南大学 | 二茂铁-黄连素/吲哚美辛@葡萄糖氧化酶@透明质酸纳米药物、制备方法与应用 |
CN113081965A (zh) * | 2021-04-16 | 2021-07-09 | 烟台大学 | 一种基于ros敏感及h2s响应的多功能脂质体及其制备方法和应用 |
CN114377050A (zh) * | 2022-02-15 | 2022-04-22 | 吉林大学 | 一种含葵花盘小分子的抗痛风组合物 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9044476B2 (en) * | 2013-01-16 | 2015-06-02 | Taipei Medical University | Use of uraria in promoting osteogenesis or providing neuroprotection |
-
2023
- 2023-01-07 CN CN202310022311.7A patent/CN116808172B/zh active Active
Patent Citations (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011079410A1 (zh) * | 2009-12-28 | 2011-07-07 | Ling Peixue | 含向日葵提取物的药物组合物、制备方法及用途 |
WO2015181393A1 (en) * | 2014-05-30 | 2015-12-03 | Per-Johan Jakobsson | Novel sfti and cyclotide based peptides |
CN104523772A (zh) * | 2014-12-08 | 2015-04-22 | 浙江工业大学 | 黄蜀葵花生物总碱提取物及其制备方法与应用 |
CN105125610A (zh) * | 2015-09-16 | 2015-12-09 | 吉林大学 | 葵花盘水解复合粉剂在制备治疗或缓解高尿酸痛风症药物中的应用 |
CN105753935A (zh) * | 2016-05-06 | 2016-07-13 | 洮南市金塔生物科技有限公司 | 一种葵花盘小分子肽及制备方法和医用用途 |
CN105878322A (zh) * | 2016-05-06 | 2016-08-24 | 洮南市金塔生物科技有限公司 | 一种结晶酶解法制备的葵花盘提取物及其制备方法 |
CN105920067A (zh) * | 2016-05-06 | 2016-09-07 | 洮南市金塔生物科技有限公司 | 一种含多糖、黄酮和生物碱的葵花盘提取物及其制备方法 |
CN107961366A (zh) * | 2018-01-15 | 2018-04-27 | 吉林省倍减生物科技有限公司 | 葵花小分子肽在降尿酸溶解痛风石修复肾功能中的应用 |
CN108324938A (zh) * | 2018-03-01 | 2018-07-27 | 中国科学院过程工程研究所 | 一种颗粒型佐剂及其制备方法和应用 |
CN108354956A (zh) * | 2018-03-08 | 2018-08-03 | 吉林大学 | 葵花盘粉及其有效成分在制备修复受损肝细胞药物中的应用 |
AU2018100458A4 (en) * | 2018-04-14 | 2018-06-21 | Jilin Province Beijian Biological Technology Co., Ltd. | Application Of Sunflower Small Molecule Peptide In The Repair Of Renal Function By Decreasing Uric Acid And Dissolving Chalk Stones |
CN108434189A (zh) * | 2018-05-21 | 2018-08-24 | 长春市万象鹰豪商贸有限公司 | 一种向日葵花盘总黄酮及其提取工艺和应用 |
CN108379318A (zh) * | 2018-05-31 | 2018-08-10 | 吉林大学 | 一种具有黄嘌呤氧化酶抑制活性的向日葵花盘水提物、制备方法及其应用 |
CN110251545A (zh) * | 2019-06-20 | 2019-09-20 | 中国药科大学 | 一种葵花盘提取物及其制备方法和应用 |
CN110354079A (zh) * | 2019-08-28 | 2019-10-22 | 中国药科大学 | 一种脂质过氧化物生成器及其制备方法和应用 |
RU2714891C1 (ru) * | 2019-10-15 | 2020-02-20 | Общество С Ограниченной Ответственностью "Научно-Исследовательская Фирма "Ультрасан" (Ооо Ниф "Ультрасан") | Ферроценилалкильные производные дипиразолилселенидов в качестве биологически активных соединений и способы их получения (варианты) |
AU2020101274A4 (en) * | 2020-05-14 | 2020-08-13 | Jilin Province TeyiFood Biotechnology Company Limited | Sunflower disc extract and medical use thereof in the treatment of constipation |
CN112505117A (zh) * | 2020-11-11 | 2021-03-16 | 军事科学院军事医学研究院军事兽医研究所 | 一种二茂铁纳米花、电化学适配体生物传感器体系及其制备方法和应用 |
CN112641760A (zh) * | 2021-01-08 | 2021-04-13 | 东南大学 | 二茂铁-黄连素/吲哚美辛@葡萄糖氧化酶@透明质酸纳米药物、制备方法与应用 |
CN113081965A (zh) * | 2021-04-16 | 2021-07-09 | 烟台大学 | 一种基于ros敏感及h2s响应的多功能脂质体及其制备方法和应用 |
CN114377050A (zh) * | 2022-02-15 | 2022-04-22 | 吉林大学 | 一种含葵花盘小分子的抗痛风组合物 |
Non-Patent Citations (5)
Title |
---|
De novo birth and stepwise evolution of a seed peptide;Achala S. Jayasena;《the University of western australia》;第1-221页 * |
Ferrocene-Peptide Bioconjugates;Toshiyuki Moriuchi et al.;《Top Organomet Chem》;第143-175页 * |
Natural structural diversity within a conserved cyclic peptide scaffold;Alysha G. Elliott et al.;《Amino Acids》;第1-14页 * |
Soy Lecithin-Derived Liposomal Delivery Systems: Surface Modification and Current Applications;Ngoc Thuy Trang Le et al.;《Int. J. Mol. Sci.》;第20卷;第1-27页 * |
葵花盘粉有效成分对小鼠高尿酸血症的治疗作用;戴惠咛等;《吉林大学学报(医学版)》;第44卷(第2期);第327-332页 * |
Also Published As
Publication number | Publication date |
---|---|
CN116808172A (zh) | 2023-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107335049B (zh) | 菊科类型环肽化合物作为cGAS-STING信号通路抑制剂的应用 | |
FR2522267A1 (fr) | Glycoproteines a activite antitumorale, leur procede de preparation et leur application therapeutique | |
CN101874807B (zh) | 以羊毛固醇及茯苓萃取物治疗恶病质的用途 | |
WO2022121986A1 (zh) | 一种防治神经退行性疾病的新型药物 | |
WO2013078764A1 (zh) | 1β-羟基土木香内酯在制备防治类风湿关节炎的药物中的应用 | |
CN116808172B (zh) | 葵花盘肽、复合脂质体及其在制备降低尿酸和溶解痛风石产品中的应用 | |
WO1996032123A1 (en) | Pharmaceutical preparations derived from korean mistletoe | |
Lü et al. | Apocynum leaf extract inhibits the progress of atherosclerosis in rats via the AMPK/mTOR pathway | |
CN111202737B (zh) | 雷公藤红素酰胺衍生物在制备治疗自身性免疫疾病药物的应用 | |
CN116948901A (zh) | 食窦魏斯氏菌d-2胞外多糖在抑制结肠癌细胞中的应用 | |
CN103340880B (zh) | 2,3-二羟基苯甲酸酯类化合物在制备治疗糖尿病的食品和药物中的应用 | |
US5585467A (en) | Proteoglycan(G009) effective in enhancing antitumor immunity | |
CN109045107B (zh) | 一种治疗类风湿关节炎的药物及制备方法 | |
EP0563383A1 (en) | (ganoderma lucidium) iy009 which produces proteoglycan (g009) having effect of enhancing antitumor immunity | |
FR2499409A1 (fr) | Agent therapeutique a base d'une protease acide, pour le traitement des troubles allergiques, des maladies avec immunocomplexe et des tumeurs | |
CN115645416B (zh) | Calvasterol A在制备治疗肝纤维化药物中的应用 | |
CN111000908A (zh) | 蓝布正提取物在用于制备防治自身免疫疾病药物中的应用 | |
CN116947794B (zh) | 一种四环环系重排桉烷型倍半萜类化合物及其制备方法和应用、药物组合物及其应用 | |
JPS63209579A (ja) | 冬虫夏草の培養法 | |
CN113456695B (zh) | 琴叶榕石油醚部位在制备预防或治疗肝癌药物中的应用 | |
CN110721193B (zh) | 锁阳总多糖在制备治疗哮喘药物中的应用 | |
CN114652714B (zh) | 大环内酯在抗胰腺癌中的应用 | |
CN114478700B (zh) | 鸡冠花子中荨麻科类型环肽的制备方法及其在抗肿瘤药物中的应用 | |
CN108822175B (zh) | 3,16-雄甾烯二酮类化合物及其应用 | |
CN117323352A (zh) | 一种具有足细胞保护活性的冬虫夏草提取物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Gong Shuchu Inventor after: Lin Huanbing Inventor after: Wang Xiaojuan Inventor after: Zhao Ce Inventor before: Wang Xiaojuan Inventor before: Zhao Ce |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20240104 Address after: No. 5, Unit 1, Building 2, No. 234 Laodong South Road, Yushui District, Xinyu City, Jiangxi Province, 338000 Applicant after: Gong Shuchu Address before: 100000 foreign enterprise service company, Chaoyang District, Beijing Applicant before: Wang Xiaojuan |
|
GR01 | Patent grant | ||
GR01 | Patent grant |